Opinion: STAT+: Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D
The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the…
Category: finance
STAT+: Private equity giant Carlyle to acquire biotech venture capital firm Abingworth
The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced…
.jpg)
STAT+: 5 technology trends drawing investment as health care moves into the home
With Medicare expected to cover a projected 80 million people by 2030, entrepreneurs and investors…
STAT+: UnitedHealth’s deal with LHC highlights broader interest in home health industry
UnitedHealth Group’s proposed $5.4 billion buyout of home health and hospice provider LHC Group serves…
Opinion: How to fix the two-tier U.S. health payment system
How the U.S. pays for health care is neither efficient nor fair. Despite spending an…
STAT+: A hospital lobbying juggernaut makes an unlikely pivot into venture capital
The American Hospital Association is a lobbying powerhouse, championing the interests of its thousands of…
STAT+: TeamHealth hit with another lawsuit for alleged overbilling, this time from an employer
A Louisiana employer filed a class-action lawsuit against TeamHealth, alleging the private-equity-backed physician staffing firm…
STAT+: Patients are flocking back to hospitals, but volumes are at the mercy of Covid surges, new documents show
Hospitals and outpatient clinics filled up with patients early last year, as vaccines and the…
.jpg)
STAT+: Arrowhead shareholders urged not to approve ‘excessive’ compensation for non-executive directors
In an unusual move, a prominent shareholder advisory firm is urging investors in Arrowhead Pharmaceuticals…
STAT+: Few public biotech companies disclose environmental, social, and governance steps
Environmental, social, and governance issues are gaining greater attention among investors, but only 30% of…
STAT+: Even as it struggles, startup insurer Bright Health deepens its ties to Cigna
Bright Health is hemorrhaging money, raising questions not only about its future but also about…
Opinion: STAT+: What biotech can learn from past stock market downturns
“Dumpster fire.” “Biotech bear market.” “A market rout.” Going by recent descriptions of the performance of…
Opinion: If academic medicine is serious about diversity, its institutions need to pay up
As I began interviewing for my first post-fellowship position as a neuro-oncologist, I immediately realized…
STAT+: 3 biotech trends to watch in 2022
It’s been a weird year for biotech stocks. One major index peaked in February, but…
STAT+: Oracle to buy electronic health records giant Cerner for $28.3 billion
In what will be the year’s largest deal in health tech, software giant Oracle has…
STAT+: Health tech’s sky-high projections in 2021 have already been punctured
The health technology sector has seen extraordinary enthusiasm among private and public investors this year….
STAT+: Biotech investor Eli Casdin on biotech’s bad December
Biotech investors are having some not-so-happy holidays. In the last few months, several major funds…
STAT+: At biotech venture capital firms, collecting ‘consulting fees’ from startups has become widespread
Some of the biggest names in biotech venture capital have charged their startups millions of…
STAT+: Socially responsible investor coalitions push greater access to medicines in shareholder proposals
Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor…
STAT+: Flagship Pioneering’s Noubar Afeyan on the crazy idea behind Moderna and professional entrepreneurs
On his desk — placed so its visible on his Zoom calls — Flagship Pioneering…
STAT+: GlaxoSmithKline’s Emma Walmsley predicts a ‘landmark’ 2022 for the company
Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley —…
STAT+: By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction
In a first-of-its-kind move by a drug maker, Teva Pharmaceuticals (TEVA) recently sold $5 billion…
The Catholic hospital system Ascension is running a Wall Street-style private equity fund
WASHINGTON — America’s largest Catholic hospital system, Ascension, has quietly built out a strikingly unusual…
STAT+: How America’s largest Catholic hospital system is moonlighting as a private equity firm
The nation’s largest Catholic hospital system, a sprawling behemoth of more than 140 hospitals called…
STAT+: Moderna millionaires and the double-edged sword of stock market riches
In just a few years, Moderna went from stock market dud to moonshot, a prime example…
STAT+: Moderna, making billions from its vaccine, bets on a genome-editing startup
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, made waves back in August…
STAT+: Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?
Students, employees, and professors at a research institution generally pledge that in the event they…
STAT+: Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter…
STAT+: ‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role
Former Merck CEO Ken Frazier, famous for building the drugmaker into one of the world’s…
Watch: What’s up with tranched deals in biotech?
Tranche is a French word meaning slice, and that’s pretty much what it means in…
STAT+: In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding
In today’s biotech job market — where competition for people with in-demand experience is fiercer…
STAT+: Graduate students launch an entrepreneurship program to bring new faces to biotech
A group of graduate students is expanding a Boston-based biotech entrepreneurship program across the country,…
STAT+: Big business lobbies bitterly divided over drug pricing reform
WASHINGTON — Groups representing companies like Apple, Tesla, and Boeing are clashing with Washington’s wealthiest…
STAT+: Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail
In an unusual step, the European Commission plans to intervene in the recent merger between…
STAT+: Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal
Good morning, all, I hope everyone is off to a good start. Ed is out…
STAT+: In another sign of RNA’s growing popularity, the cancer startup Replicate is relaunching
A California startup is putting a new spin on a now-familiar idea: using RNA as…
STAT+: STAT+ Conversation: Which biotech venture capitalist funds performed best during the pandemic?
Editor’s note: A livestream of the conversation will be embedded below at 2 p.m. ET….
STAT+: Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion
Cityblock Health, a startup using technology to deliver well-rounded primary care to people covered by…
STAT+: Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms
Flagship Pioneering is on track to return its investors’ money an eye-popping 15 times over,…
STAT+: Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal
Just days before Pfizer (PFE) announced plans to acquire Medivation six years ago, the former…
With Amwell’s deal, the acquisition race heats up in telehealth
You’re reading the web edition of STAT Health Tech, our guide to how tech is…
STAT+: The most intriguing health tech deals of the year (so far)
In the world of digital health, money is flying around like never before. All that…
STAT+: Inside the ‘land grab’ for virtual-first care: how an unprecedented flurry of deals is shaping the new digital health landscape
Teladoc’s blockbuster merger with Livongo in 2020 would’ve been unthinkable just a few years ago….
STAT+: Pear Therapeutics to go public in $1.6 billion SPAC merger
Barreling forward with its early momentum in the digital therapeutics market, Pear Therapeutics announced Tuesday…
STAT+: Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge
The Open Society Foundations, one of the world’s largest backers of public health initiatives, is…
Watch: SPACs are all the rage, but what are they? STAT explains
Wall Street’s hottest new trend is a 1980s retread: Private firms are merging with so-called…
STAT+: Regeneron shareholders urged to boot board member over executive pay practices
Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove the board…
STAT+: One Medical eyes the full lifespan with acquisition of Medicare-focused Iora Health
One Medical announced its plan on Monday to acquire Iora Health, expanding its primary care…
Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding
“Mount up! Let’s hear more about this unicorn.” So begins every episode of a new…
STAT+: Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval
A lymphoma drug that was approved later than expected by regulators is at the center…